These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 33085507)

  • 21. Hydroxychloroquine or Chloroquine for Treatment or Prophylaxis of COVID-19: A Living Systematic Review.
    Hernandez AV; Roman YM; Pasupuleti V; Barboza JJ; White CM
    Ann Intern Med; 2020 Aug; 173(4):287-296. PubMed ID: 32459529
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Insights into antiviral mechanisms of remdesivir, lopinavir/ritonavir and chloroquine/hydroxychloroquine affecting the new SARS-CoV-2.
    Uzunova K; Filipova E; Pavlova V; Vekov T
    Biomed Pharmacother; 2020 Nov; 131():110668. PubMed ID: 32861965
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Emergency Authorization of Chloroquine and Hydroxychloroquine for Treatment of COVID-19.
    Piszczatoski CR; Powell J
    Ann Pharmacother; 2020 Aug; 54(8):827-831. PubMed ID: 32389025
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of chloroquine or hydroxychloroquine in treatment of COVID-19: is it ethical?
    Allam MF; Andraous F
    Cent Eur J Public Health; 2020 Sep; 28(3):246-247. PubMed ID: 32997483
    [No Abstract]   [Full Text] [Related]  

  • 25. Hydroxychloroquine/ chloroquine as a treatment choice or prophylaxis for Covid-19 at the primary care level in developing countries: A Primum non Nocere dilemma.
    Medina MT; Moncada SS
    J Neurol Sci; 2020 Aug; 415():116972. PubMed ID: 32534369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Benefit v. risk when using chloroquine in patients with severe COVID-19 disease.
    Decloedt EH; Reuter H; Allwood B; Parker A; Koegelenberg CFN; Blockman M; Taljaard J
    S Afr Med J; 2020 Apr; 110(5):12903. PubMed ID: 32657706
    [No Abstract]   [Full Text] [Related]  

  • 27. Need for Transparency and Reliable Evidence in Emergency Use Authorizations for Coronavirus Disease 2019 (COVID-19) Therapies.
    Zhai MZ; Lye CT; Kesselheim AS
    JAMA Intern Med; 2020 Sep; 180(9):1145-1146. PubMed ID: 32427277
    [No Abstract]   [Full Text] [Related]  

  • 28. COVID-19 prevention and treatment: A critical analysis of chloroquine and hydroxychloroquine clinical pharmacology.
    White NJ; Watson JA; Hoglund RM; Chan XHS; Cheah PY; Tarning J
    PLoS Med; 2020 Sep; 17(9):e1003252. PubMed ID: 32881895
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Brief Review of Chloroquine and Hydroxychloroquine Toxicity and Management.
    Lebin JA; LeSaint KT
    West J Emerg Med; 2020 Jun; 21(4):760-763. PubMed ID: 32726238
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hydroxychloroquine prophylaxis for COVID-19 contacts in India.
    Rathi S; Ish P; Kalantri A; Kalantri S
    Lancet Infect Dis; 2020 Oct; 20(10):1118-1119. PubMed ID: 32311324
    [No Abstract]   [Full Text] [Related]  

  • 31. Chloroquine and Hydroxychloroquine in COVID-19: Practice Implications for Healthcare Professionals.
    Mallhi TH; Ahmad A; Butt MH; Misbah S; Khan YH; Alotaibi NH
    J Coll Physicians Surg Pak; 2020 Oct; 30(10):124-128. PubMed ID: 33115586
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ventricular arrhythmia risk due to chloroquine / hydroxychloroquine treatment for COVID-19: Should it be given.
    Malviya A
    Indian Heart J; 2020; 72(2):131-132. PubMed ID: 32534688
    [No Abstract]   [Full Text] [Related]  

  • 33. Chiral switches of chloroquine and hydroxychloroquine: potential drugs to treat COVID-19.
    D'Acquarica I; Agranat I
    Drug Discov Today; 2020 Jul; 25(7):1121-1123. PubMed ID: 32371138
    [No Abstract]   [Full Text] [Related]  

  • 34. Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach.
    Tilangi P; Desai D; Khan A; Soneja M
    Lancet Infect Dis; 2020 Oct; 20(10):1119-1120. PubMed ID: 32450054
    [No Abstract]   [Full Text] [Related]  

  • 35. Hydroxychloroquine for chemoprophylaxis in COVID-19: A case of motivated perception?
    Manjunath BG; Tyagi D; Chaudhry D; Singh PK
    Indian J Med Res; 2020 Jul & Aug; 152(1 & 2):116-118. PubMed ID: 32773415
    [No Abstract]   [Full Text] [Related]  

  • 36. Do we have enough evidence to use chloroquine/hydroxychloroquine as a public health panacea for COVID-19?
    Palmeira VA; Costa LB; Perez LG; Ribeiro VT; Lanza K; Silva ACSE
    Clinics (Sao Paulo); 2020; 75():e1928. PubMed ID: 32401962
    [No Abstract]   [Full Text] [Related]  

  • 37. Use of Chloroquine and Hydroxychloroquine in COVID-19 and Cardiovascular Implications: Understanding Safety Discrepancies to Improve Interpretation and Design of Clinical Trials.
    Oren O; Yang EH; Gluckman TJ; Michos ED; Blumenthal RS; Gersh BJ
    Circ Arrhythm Electrophysiol; 2020 Jun; 13(6):e008688. PubMed ID: 32436730
    [No Abstract]   [Full Text] [Related]  

  • 38. COVID-19 and hydroxychloroquine: Let the available data speak for themselves.
    Paliani U; Cardona A
    Eur J Intern Med; 2020 Oct; 80():121. PubMed ID: 32709544
    [No Abstract]   [Full Text] [Related]  

  • 39. Safety considerations for chloroquine and hydroxychloroquine in the treatment of COVID-19.
    Gevers S; Kwa MSG; Wijnans E; van Nieuwkoop C
    Clin Microbiol Infect; 2020 Sep; 26(9):1276-1277. PubMed ID: 32422406
    [No Abstract]   [Full Text] [Related]  

  • 40. Response to the editorial "COVID-19 in patients with cardiovascular diseases": Covid-19 treatment with hydroxychloroquine or chloroquine and azithromycin: A potential risk of Torsades de Pointes.
    Funck-Brentano C; Salem JE; Nguyen LS; Drici MD; Roden DM
    Arch Cardiovasc Dis; 2020 May; 113(5):367-368. PubMed ID: 32331979
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.